{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T22:20:40Z","timestamp":1790202040359,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,7,1]],"date-time":"2008-07-01T00:00:00Z","timestamp":1214870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,12,2]],"date-time":"2022-12-02T00:00:00Z","timestamp":1669939200000},"content-version":"vor","delay-in-days":5267,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["amjtransplant.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["American Journal of Transplantation"],"published-print":{"date-parts":[[2008,7]]},"DOI":"10.1111\/j.1600-6143.2008.02272.x","type":"journal-article","created":{"date-parts":[[2008,5,28]],"date-time":"2008-05-28T17:27:12Z","timestamp":1211995632000},"page":"1384-1392","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":147,"title":["Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients"],"prefix":"10.1016","volume":"8","author":[{"given":"B.L.","family":"Kasiske","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"de Mattos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.M.","family":"Flechner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Gallon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.-U.","family":"Meier-Kriesche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.R.","family":"Weir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Wilkinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"4 Suppl 3","key":"10.1111\/j.1600-6143.2008.02272.x_bib1","first-page":"I","article-title":"Kidney Disease Outcomes Quality Initiative (K\/DOQI) Group. K\/DOQI clinical practice guidelines for management of dyslipidemias in patients with kidney disease","volume":"41","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib2","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1681\/ASN.V71158","article-title":"Cardiovascular disease after renal transplantation","volume":"7","author":"Kasiske","year":"1996","journal-title":"J Am Soc Nephrol"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib3","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/j.1523-1755.2004.00751.x","article-title":"Predicting coronary heart disease in renal transplant recipients: A prospective study","volume":"66","author":"Ducloux","year":"2004","journal-title":"Kidney Int"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib4","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1097\/00007890-199904150-00017","article-title":"for Sirolimus European Renal Transplant Study Group. Sirolimus (rapamycin)-based therapy in human renal transplantation: Similar efficacy and different toxicity compared with cyclosporine","volume":"67","author":"Groth","year":"1999","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib5","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/S0140-6736(00)02480-6","article-title":"for Rapamune US Study Group. Efficacy of sirolimus compared with azathioprine for reduction of acute renal allograft rejection: A randomised multicentre study","volume":"356","author":"Kahan","year":"2000","journal-title":"Lancet"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib6","doi-asserted-by":"crossref","first-page":"1252","DOI":"10.1097\/00007890-200004150-00009","article-title":"Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients","volume":"69","author":"Kreis","year":"2000","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib7","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1034\/j.1600-6143.2002.20610.x","article-title":"Effects of sirolimus on lipids in renal allograft recipients: An analysis using the Framingham risk model","volume":"2","author":"Blum","year":"2002","journal-title":"Am J Transplant"},{"issue":"Suppl 3 A","key":"10.1111\/j.1600-6143.2008.02272.x_bib8","doi-asserted-by":"crossref","first-page":"177S","DOI":"10.1016\/S0041-1345(03)00232-X","article-title":"Safety and efficacy of sirolimus in kidney transplant patients and in patients with coronary artery disease undergoing angioplasty","volume":"35","author":"Tedesco Silva","year":"2003","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib9","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1097\/00007890-200210270-00002","article-title":"Kidney transplantation without calcineurin inhibitor drugs: A prospective, randomized trial of sirolimus versus cyclosporine","volume":"74","author":"Flechner","year":"2002","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib10","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1097\/01.tp.0000235823.09788.f6","article-title":"Living related kidney transplantation without calcineurin inhibitors: Initial experience in a Mexican center","volume":"82","author":"Martinez-Mier","year":"2006","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib11","doi-asserted-by":"crossref","first-page":"2522","DOI":"10.1111\/j.1600-6143.2007.01976.x","article-title":"Sirolimus versus cyclosporine in kidney recipients receiving Thymoglobulin\u00ae, mycophenolate mofetil and a 6-month course of steroids","volume":"7","author":"B\u00fcchler","year":"2007","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib12","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1097\/01.TP.0000062837.99400.60","article-title":"Randomized trial of tacrolimus in combination with sirolimus or mycophenolate mofetil in kidney transplantation: Results at 6 months","volume":"75","author":"Gonwa","year":"2003","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib13","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1097\/01.TP.0000101495.22734.07","article-title":"A randomized long-term trial of tacrolimus\/sirolimus versus tacrolimus\/mycophenolate mofetil versus cyclosporine (NEORAL)\/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year","volume":"77","author":"Ciancio","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib14","doi-asserted-by":"crossref","first-page":"1934","DOI":"10.1097\/01.TP.0000071301.86299.75","article-title":"A prospective randomized multicenter study of tacrolimus in combination with sirolimus in renal-transplant recipients","volume":"75","author":"van Hooff","year":"2003","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib15","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1111\/j.1600-6143.2005.01193.x","article-title":"Tacrolimus combined with two different dosages of sirolimus in kidney transplantation: Results of a multicenter study","volume":"6","author":"Vitko","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib16","doi-asserted-by":"crossref","first-page":"2521","DOI":"10.1111\/j.1600-6143.2005.01063.x","article-title":"Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil inde novorenal transplant patients","volume":"5","author":"Vitko","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib17","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1097\/01.TP.0000164352.65613.24","article-title":"Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: A 3-year randomized, multicenter, phase III study","volume":"80","author":"Lorber","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib18","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1097\/01.TP.0000141094.34903.54","article-title":"Everolimus (Certican) 12-month safety and efficacy versus mycophenolate mofetil in de novo renal transplant recipients","volume":"78","author":"Vitko","year":"2004","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib19","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1111\/j.1600-6143.2005.01177.x","article-title":"Complete avoidance of calcineurin inhibitors in renal transplantation: A randomized trial comparing sirolimus and tacrolimus","volume":"6","author":"Larson","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib20","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1097\/01.tp.0000258586.52777.4c","article-title":"Kidney transplantation with sirolimus and mycophenolate mofetil-based immunosuppression: 5-year results of a randomized prospective trial compared to calcineurin inhibitor drugs","volume":"83","author":"Flechner","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib21","doi-asserted-by":"crossref","first-page":"1244","DOI":"10.1097\/00007890-200110150-00011","article-title":"Effect of sirolimus on the metabolism of apoB100-containing lipoproteins in renal transplant patients","volume":"72","author":"Hoogeveen","year":"2001","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib22","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1194\/jlr.M100392-JLR200","article-title":"Effects of sirolimus on plasma lipids, lipoprotein levels, and fatty acid metabolism in renal transplant patients","volume":"43","author":"Morrisett","year":"2002","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib23","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1097\/01.tp.0000286095.55685.e9","article-title":"Sirolimus modifies cholesterol homeostasis in hepatic cells: A potential molecular mechanism for sirolimus-associated dyslipidemia","volume":"84","author":"Ma","year":"2007","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib24","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1093\/ndt\/15.6.928","article-title":"Hyperlipidaemia and post-heparin lipase activities in renal transplant recipients treated with sirolimus or cyclosporin A","volume":"15","author":"Massy","year":"2000","journal-title":"Nephrol Dial Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib25","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1038\/nature02866","article-title":"Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity","volume":"431","author":"Um","year":"2004","journal-title":"Nature"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib26","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1097\/01.tp.0000187869.04180.7f","article-title":"Apolipoprotein E genotypes as predictors of high-risk groups for developing hyperlipidemia in kidney transplant recipients undergoing sirolimus treatment","volume":"80","author":"Maluf","year":"2005","journal-title":"Transplantation"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib27","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1034\/j.1600-6143.2003.00094.x","article-title":"Protective effect of the immunosuppressant sirolimus against aortic atherosclerosis in apo E-deficient mice","volume":"3","author":"Elloso","year":"2003","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib28","doi-asserted-by":"crossref","first-page":"F43","DOI":"10.1152\/ajprenal.00181.2004","article-title":"Effects of sirolimus on mesangial cell cholesterol homeostasis: A novel mechanism for its action against lipid-mediated injury in renal allografts","volume":"289","author":"Varghese","year":"2005","journal-title":"Am J Physiol Renal Physiol"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib29","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.atherosclerosis.2003.09.003","article-title":"Rapamycin attenuates atherosclerosis induced by dietary cholesterol in apolipoprotein-deficient mice through a p27 Kip1-independent pathway","volume":"172","author":"Castro","year":"2004","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib30","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1016\/j.cellimm.2007.01.002","article-title":"Generation of HSP60-specific regulatory T cell and effect on atherosclerosis","volume":"243","author":"Yang","year":"2006","journal-title":"Cell Immunol"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib31","doi-asserted-by":"crossref","first-page":"H2721","DOI":"10.1152\/ajpheart.01174.2006","article-title":"Anti-atherosclerotic effects of sirolimus on human vascular smooth muscle cells","volume":"292","author":"Ma","year":"2007","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib32","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: Results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib33","first-page":"313","article-title":"Cholesterol lowering with statin drugs, risk of stroke, and total mortality","volume":"278","author":"Hebert","year":"1997","journal-title":"An overview of randomized trials. JAMA"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib34","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/S0140-6736(03)12948-0","volume":"361","author":"Sever","year":"2003","journal-title":"Lancet"},{"issue":"Suppl 7","key":"10.1111\/j.1600-6143.2008.02272.x_bib35","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1111\/j.1600-6135.2004.0355.x","article-title":"Clinical practice guidelines for managing dyslipidemias in kidney transplant patients: A report from the Managing Dyslipidemias in Chronic Kidney Disease Work Group of the National Kidney Foundation Kidney Disease Outcomes Quality Initiative","volume":"4","author":"Kasiske","year":"2004","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib36","doi-asserted-by":"crossref","first-page":"2024","DOI":"10.1016\/S0140-6736(03)13638-0","article-title":"Effect of fluvastatin on cardiac outcomes in renal transplant recipients: A multicentre, randomised, placebo-controlled trial","volume":"361","author":"Holdaas","year":"2003","journal-title":"Lancet"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib37","doi-asserted-by":"crossref","unstructured":"National Institutes of Health, National Heart, Lung, and Blood Institute. Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). Executive Summary. May 2001. Report No. 01-3670.","DOI":"10.1001\/jama.285.19.2486"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib38","doi-asserted-by":"crossref","first-page":"766","DOI":"10.2215\/CJN.04131206","article-title":"The unique character of cardiovascular disease in chronic kidney disease and its implications for treatment with lipid-lowering drugs","volume":"2","author":"Nogueira","year":"2007","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib39","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"Heart Protection Study Collaborative Group. MRC\/BHF heart protection study of cholesterol lowering with simvastatin in 20536 high-risk individuals: A randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib40","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: Prospective meta-analysis of data from 90 056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib41","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1111\/j.1600-6143.2006.01263.x","article-title":"A retrospective analysis of ezetimibe treatment in renal transplant recipients","volume":"6","author":"Buchanan","year":"2006","journal-title":"Am J Transplant"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib42","doi-asserted-by":"crossref","first-page":"1033","DOI":"10.1016\/j.transproceed.2004.12.231","article-title":"Treatment of hypercholesterolemia with ezetimibe in the kidney transplant population","volume":"37","author":"Puthenparumpil","year":"2005","journal-title":"Transplant Proc"},{"key":"10.1111\/j.1600-6143.2008.02272.x_bib43","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1111\/j.1600-6143.2007.01825.x","article-title":"Early withdrawal of calcineurin inhibitors and rescue immunosuppression with sirolimus-based therapy in renal transplant recipients with moderate to severe renal dysfunction","volume":"7","author":"Wali","year":"2007","journal-title":"Am J Transplant"}],"container-title":["American Journal of Transplantation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1600-6143.2008.02272.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522055691?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1600613522055691?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1600-6143.2008.02272.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T04:45:21Z","timestamp":1761626721000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1600613522055691"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,7]]},"references-count":43,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2008,7]]}},"alternative-id":["S1600613522055691"],"URL":"https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02272.x","relation":{},"ISSN":["1600-6135"],"issn-type":[{"value":"1600-6135","type":"print"}],"subject":[],"published":{"date-parts":[[2008,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mammalian Target of Rapamycin Inhibitor Dyslipidemia in Kidney Transplant Recipients","name":"articletitle","label":"Article Title"},{"value":"American Journal of Transplantation","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1111\/j.1600-6143.2008.02272.x","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 American Society of Transplantation & American Society of Transplant Surgeons. Published by Elsevier Inc. All rights reserved. Published by Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}